Specify a stock or a cryptocurrency in the search bar to get a summary
BioSenic S.A.
BIOSBioSenic S.A., a biotech company, focuses on developing clinical assets. Its technologies include cutting-edge allogeneic cell and gene therapy platform with differentiated bone marrow sourced mesenchymal stromal cells, which can be stored at the point of use in the hospital; and Arsenic TriOxide platform for use in immuno-oncology to treat graft-versus-host disease, systemic lupus erythematosus, and systemic sclerosis. The company's investigational medicinal product is ALLOB, which is in a Phase IIb clinical trial in patients with difficult tibial fractures' and ArsciCor, which is in Phase III in GvHD is being prepared with an oral treatment. BioSenic S.A. is based in Mont-Saint-Guibert, Belgium. Address: Building H (box 24), Mont-Saint-Guibert, Belgium, 1435
Analytics
WallStreet Target Price
0.09 EURP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures BIOS
Dividend Analytics BIOS
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History BIOS
Stock Valuation BIOS
Financials BIOS
Results | 2019 | Dynamics |